Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Colorectal cancer (CRC) is a heterogeneous disease with variable clinical aggressiveness.
• Treatment resistance limits the efficacy of current therapies, necessitating novel drug combinations.
• Pevonedistat, a NEDD8-activating enzyme inhibitor, previously stabilized tumors in aggressive CRC models.

Purpose of the Study:

• To identify effective drug combinations with pevonedistat for colorectal cancer.
• To investigate the potential of targeting the EGFR signaling pathway in combination with NEDD8 inhibition.

Main Methods:

• Conducted a synthetic lethality screen using an shRNA library targeting 200 drug-target genes in four CRC cell lines.
• Utilized BRAF-mutant and RAS/RAF wild-type CRC models for validation.
• Performed in vitro and in vivo experiments to assess combined pathway blockade.

Main Results:

• EGFR signaling pathway genes were identified as key hits in the drug-target screen.
• Combined blockade of NEDD8 and EGFR pathways significantly increased growth arrest and apoptosis.
• The combination therapy effectively blunted compensatory feedback loops observed with single treatments.

Conclusions:

• Interference with the EGFR pathway is a viable strategy for combination therapy with pevonedistat in CRC.
• Combined NEDD8 and EGFR pathway inhibition offers therapeutic opportunities for specific, aggressive CRC patient populations.
• This approach may overcome resistance mechanisms and improve patient outcomes in colorectal cancer.